1
|
Gialaim Purcino dos Reis FC, de Menêses AG, Mazoni SR, Pereira Silveira RCDC, Diniz dos Reis PE, Vasques CI. Topical interventions for preventing hand-foot syndrome resulting from antineoplastic therapy: A scoping review. Rev Esc Enferm USP 2023; 57:e20220107. [PMID: 37947365 PMCID: PMC10642291 DOI: 10.1590/1980-220x-reeusp-2023-0107en] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Accepted: 09/05/2023] [Indexed: 11/12/2023] Open
Abstract
OBJECTIVE To map topical interventions used to prevent hand-foot syndrome in cancer patients undergoing antineoplastic therapy. METHOD This is a scoping review reported in accordance with the recommendations of PRISMA-ScR (extension for scoping review) and the Joanna Briggs Institute Manual. The searches were carried out in the electronic databases CINAHL, Cochrane CENTRAL, EMBASE, LILACS, LIVIVO, PubMed, Scopus, Web of Science; and gray literature (Google Scholar, Pro-Quest). RESULTS The searches resulted in 12,016 references and the final sample consisted of 45 studies. A total of 42 topical interventions were identified, including: moisturizing creams, corticosteroids, acids, mapisal, silymarin, and henna. However, urea was the most cited intervention (62%). As for the presentations of the interventions, they varied among creams, ointments, gels, hydrocolloids, decoctions, patches, powders, oils, and soaps. CONCLUSION The results allowed reviewing topical interventions, with emphasis on the use of urea and moisturizing creams. However, most of the interventions identified in this review require evaluation in future studies for better understanding of their benefits.
Collapse
Affiliation(s)
| | - Amanda Gomes de Menêses
- Universidade de Brasília, Faculdade de Ciências da Saúde, Departamento de Enfermagem, Brasília, DF, Brazil
| | - Simone Roque Mazoni
- Universidade de Brasília, Faculdade de Ciências da Saúde, Departamento de Enfermagem, Brasília, DF, Brazil
| | | | | | | |
Collapse
|
2
|
Song B, Hu H, Zhang L, Ye SJ, Jin YD, Shang CL, Zhang J, Sun H, Zhang K, Yi B, Han YW, Yan J. Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicenter, phase II study (ALTER-C-001). Front Oncol 2023; 13:1238553. [PMID: 37727206 PMCID: PMC10505961 DOI: 10.3389/fonc.2023.1238553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Accepted: 08/16/2023] [Indexed: 09/21/2023] Open
Abstract
Background Anlotinib showed encouraging anti-tumor activity in metastatic colorectal cancer (mCRC). This study was designed to assess the efficacy and safety of anlotinib plus XELOX as first-line therapy in mCRC patients. Materials and Methods Eligible patients aged ≥18 with mCRC were enrolled in this multicenter, single-arm, phase II, exploratory study. Patients received at least 6 cycles of anlotinib, oxaliplatin, and capecitabine as initial therapy. Subsequently, patients received anlotinib monotherapy as maintenance therapy until tumor progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS). Results Thirty-one patients were included between December 2019 and March 2022. The median follow-up was 17.5 (95% CI, 3.0-17.5) months. The median PFS was 8.3 (95% CI, 6.3-10.0) months, with 6- and 12-month PFS rates of 82.3% (95% CI, 59.2%-93.0%) and 18.9% (95% CI, 4.8%-40.1%), respectively. Fifteen (48.4%) achieved partial response for an ORR of 48.4% (95% CI, 30.2%-66.9%). The disease control rate was 71.0% (95% CI, 52.0%-85.8%) due to 7 (22.6%) stable diseases. The median duration of response was 6.0 (95% CI, 3.6-8.0) months and 1 patient had the longest ongoing response of 17.3 months. Of 24 patients with evaluable imaging, 23 (74.2%) obtained tumor shrinkage. The median PFS (11.0 vs. 6.9 months) and ORR (66.7% vs. 60.0%) for patients with RAS/BRAF wild-type were numerically better than those with mutation. Three patients are still ongoing treatment. The grade 3 or more treatment-emergent adverse events (TEAEs) were mainly hypertension (12.9%) and decreased neutrophil count (12.9%). Four (12.9%) had serious TEAEs, primarily including abdominal pain and incomplete intestinal obstruction. Conclusion Anlotinib plus XELOX as first-line therapy in patients with mCRC showed anti-tumor activity and safety profile, which is worth further investigation. Clinical Trial Registration chictr.org.cn, identifier ChiCTR1900028417.
Collapse
Affiliation(s)
- Bo Song
- Department of Gastrointestinal Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - Hai Hu
- Department of Gastrointestinal Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - Li Zhang
- Department of Medical Oncology, Chongqing University Three Gorges Hospital, Chongqing, China
| | - Su-Juan Ye
- Department of Medical Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
| | - Yong-Dong Jin
- Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - Chang-Ling Shang
- Department of Medical Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
| | - Jun Zhang
- Department of Medical Oncology, Chongqing University Three Gorges Hospital, Chongqing, China
| | - Hao Sun
- Gastrointestinal Cancer Center, Chongqing University Cancer Hospital, Chongqing, China
| | - Ke Zhang
- Department of Gastrointestinal Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - Bo Yi
- Department of Gastrointestinal Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - Yun-Wei Han
- Department of Medical Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
| | - Jin Yan
- Department of Gastrointestinal Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| |
Collapse
|
3
|
Yoshida Y, Sasaoka S, Tanaka M, Matsumoto K, Inoue M, Satake R, Shimada K, Mukai R, Suzuki T, Iwata M, Goto F, Mori T, Mori K, Yoshimura T, Nakamura M. Analysis of drug-induced hand-foot syndrome using a spontaneous reporting system database. Ther Adv Drug Saf 2022; 13:20420986221101963. [PMID: 35646307 PMCID: PMC9136434 DOI: 10.1177/20420986221101963] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2021] [Accepted: 04/23/2022] [Indexed: 12/23/2022] Open
Abstract
Purpose The aim of our study was to assess the clinical features of hand-foot syndrome (HFS) associated with certain systemic chemotherapeutic drugs in a real-world setting using the Japanese Adverse Drug Event Report (JADER) database. Methods HFS was defined using the preferred terms from the Medical Dictionary for Regulatory Activities. We used several indices, such as the reporting odds ratios (RORs) at 95% confidence interval (CI), the time-to-onset profile of HFS, and cluster analysis. Results Of 646,779 reports (submission period: April 2004 to September 2020), 1814 reported HFS events. The RORs (95% CI) for axitinib, capecitabine, lapatinib, regorafenib, sorafenib, and sunitinib were 14.9 (11.1-20.1), 54.6 (49.2-60.6), 130.4 (110.7-153.6), 63.3 (55.2-72.6), 29.0 (25.8-32.7), and 13.9 (11.7-16.5), respectively. The analysis of time-to-onset profiles revealed that the median values (interquartile range: 25.0-75.0%) of drug-induced HFS caused by capecitabine, cisplatin, docetaxel, everolimus, regorafenib, sorafenib, and trastuzumab were 21.0 (13.0-42.0), 15.0 (10.0-82.0), 6.0 (3.0-25.0), 86.5 (67.0-90.5), 9.0 (6.0-14.0), 9.0 (6.0-14.0), and 70.0 (15.0-189.0) days, respectively. The number of clusters was set to 4. Among these, one cluster, which included capecitabine, regorafenib, and lapatinib, exhibited a higher reporting ratio and ROR of drug-induced HFS than other drugs. Conclusions The RORs and results of time-to-onset analysis obtained in this study indicated the potential risk of HFS associated with chemotherapeutic drugs. Our results suggest that health care professionals must be aware of the potential onset of drug-induced HFS with docetaxel, regorafenib, and sorafenib for at least 4 weeks; therefore, careful observation is recommended. Plain Language Summary Elucidation of the relationship between cancer drugs and risk of hand-foot syndrome: Purpose: Hand-foot syndrome (HFS) is an adverse effect of some cancer drugs, which is characterized by symptoms such as redness, swelling, blistering, and pain in the area of palms and soles. HFS reduces the quality of life of patients and can sometimes interfere with anticancer treatment plans. It is important to understand the clinical manifestations of HFS and gain knowledge that will allow for early intervention by clinicians.Methods: In this study, we used a large-scale side effect database of real-world cases for a comprehensive investigation of anticancer-drug-induced HFS. The database contained 646,779 adverse event reports from April 2004 to September 2020; among which, we identified 1814 HFS events. Using these data, we could obtain information on the relationship between 19 types of anticancer drugs and HFS, and the onset time of HFS and HFS prognosis related to each anticancer drug. Results: Our results suggest that clinicians should monitor the risk of HFS with docetaxel, regorafenib, and sorafenib for at least the first 4 weeks after drug administration. Conclusion: These findings are crucial for improving the management of the adverse effects caused by anticancer drugs.
Collapse
Affiliation(s)
- Yu Yoshida
- Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan
| | - Sayaka Sasaoka
- Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan
| | - Mizuki Tanaka
- Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan
| | - Kiyoka Matsumoto
- Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan
| | - Misaki Inoue
- Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan
| | - Riko Satake
- Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan
| | - Kazuyo Shimada
- Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan
| | - Ririka Mukai
- Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan
| | - Takaaki Suzuki
- Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan
- Gifu Prefectural Government, Gifu, Japan
| | - Mari Iwata
- Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan
- Kifune Pharmacy, Gifu, Japan
| | - Fumiya Goto
- Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan
| | - Takayuki Mori
- Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Japan
| | - Koki Mori
- Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Japan
| | | | - Mitsuhiro Nakamura
- Laboratory of Drug Informatics, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan
| |
Collapse
|
4
|
Zelman B, Lee K, Reserva J, Speiser J. A paclitaxel-induced variant of hand-foot syndrome affecting dorsal surfaces. J Cutan Pathol 2021; 48:1320-1323. [PMID: 33938036 DOI: 10.1111/cup.14040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2020] [Revised: 04/24/2021] [Accepted: 04/27/2021] [Indexed: 11/30/2022]
Affiliation(s)
- Brandon Zelman
- Department of Pathology and Laboratory Medicine, Loyola University Medical Center, Maywood, Illinois, USA
| | - Kristin Lee
- Department of Dermatology, Loyola University Medical Center, Maywood, Illinois, USA
| | - Jeave Reserva
- Department of Dermatology, Loyola University Medical Center, Maywood, Illinois, USA
| | - Jodi Speiser
- Department of Pathology and Laboratory Medicine, Loyola University Medical Center, Maywood, Illinois, USA
| |
Collapse
|
5
|
Liposome and immune system interplay: Challenges and potentials. J Control Release 2019; 305:194-209. [DOI: 10.1016/j.jconrel.2019.05.030] [Citation(s) in RCA: 76] [Impact Index Per Article: 15.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2019] [Revised: 05/15/2019] [Accepted: 05/17/2019] [Indexed: 01/20/2023]
|
6
|
Kataria PS, Kendre PP, Patel AA, Tahiliani N, Bhargav V, Parekh H. Rare occurrence of hand-foot syndrome due to paclitaxel: A rare case report. Indian J Pharmacol 2019; 50:284-286. [PMID: 30636833 PMCID: PMC6302696 DOI: 10.4103/ijp.ijp_547_17] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Hand-foot syndrome (HFS) is a relatively frequent adverse reaction to certain anticancer drugs. HFS is a type of dermatitis which has been most commonly described with 5-fluorouracil and capecitabine. However, HFS with paclitaxel is rare and has been reported sparingly in the literature. A 52-year-old male patient with recurrent carcinoma of the buccal mucosa was started on palliative chemotherapy regimen, injection paclitaxel (175 mg/m2) in combination with injection carboplatin. On post-chemotherapy day 13, the patient started developing pain, dysesthesia followed by bullae formation, and desquamation over palms and soles. Clinically, the patient had Grade 3 HFS characterized by symmetrical, tender skin lesions over the dorsal aspect of palms, and soles with desquamation necessitating interruption of treatment. Therefore, this case has been presented to be cognizant with this rare form of side effect with one of the most commonly used drug in oncology.
Collapse
Affiliation(s)
- Pritam S Kataria
- Department of Medical and Paediatric Oncology, GCRI, Ahmedabad, Gujarat, India
| | - Pradip P Kendre
- Department of Medical and Paediatric Oncology, GCRI, Ahmedabad, Gujarat, India
| | - Apurva A Patel
- Department of Medical Oncology, GCRI, Ahmedabad, Gujarat, India
| | - Nahush Tahiliani
- Department of Medical and Paediatric Oncology, GCRI, Ahmedabad, Gujarat, India
| | - Vijay Bhargav
- Department of Medical and Paediatric Oncology, GCRI, Ahmedabad, Gujarat, India
| | - Honey Parekh
- Department of Medical and Paediatric Oncology, GCRI, Ahmedabad, Gujarat, India
| |
Collapse
|
7
|
Exosomal delivery of doxorubicin enables rapid cell entry and enhanced in vitro potency. PLoS One 2019; 14:e0214545. [PMID: 30925190 PMCID: PMC6440694 DOI: 10.1371/journal.pone.0214545] [Citation(s) in RCA: 111] [Impact Index Per Article: 22.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2018] [Accepted: 03/14/2019] [Indexed: 01/15/2023] Open
Abstract
Doxorubicin is a chemotherapeutic agent that is commonly used to treat a broad range of cancers. However, significant cardiotoxicity, associated with prolonged exposure to doxorubicin, limits its continued therapeutic use. One strategy to prevent the uptake of doxorubicin into cardiac cells is the encapsulation of the drug to prevent non-specific uptake and also to improve the drugs’ pharmacokinetic properties. Although encapsulated forms of doxorubicin limit the cardiotoxicity observed, they are not without their own liabilities as an increased amount of drug is deposited in the skin where liposomal doxorubicin can cause palmar-plantar erythrodysesthesia. Exosomes are small endogenous extracellular vesicles, that transfer bioactive material from one cell to another, and are considered attractive drug delivery vehicles due to their natural origin. In this study, we generated doxorubicin-loaded exosomes and demonstrate their rapid cellular uptake and re-distribution of doxorubicin from endosomes to the cytoplasm and nucleus resulting in enhanced potency in a number of cultured and primary cell lines when compared to free doxorubicin and liposomal formulations of doxorubicin. In contrast to other delivery methods for doxorubicin, exosomes do not accumulate in the heart, thereby providing potential for limiting the cardiac side effects and improved therapeutic index.
Collapse
|
8
|
Komatsu H, Yagasaki K, Hamamoto Y, Takebayashi T. Falls and Physical Inactivity in Patients with Gastrointestinal Cancer and Hand-Foot Syndrome. Asia Pac J Oncol Nurs 2018; 5:307-313. [PMID: 29963593 PMCID: PMC5996583 DOI: 10.4103/apjon.apjon_8_18] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Objective This study aims to ascertain the incidence and association of falls and physical inactivity in patients with gastrointestinal cancer and hand-foot syndrome (HFS) after receiving chemotherapy or targeted therapy. Methods The present cross-sectional study was conducted on 50 outpatients with HFS of Grade 1 or above, according to the National Cancer Institute Common Terminology Criteria for Adverse Events, following the receipt of chemotherapy or targeted therapy for gastrointestinal cancer in Japan between November 2016 and February 2017. For measurement, Dermatology Life Quality Index (DLQI) and the International Physical Activity Questionnaire were used. Data were analyzed by logistic regression analysis. Results Of the participants, 18% experienced falls and 60% reported physical inactivity. Multivariate logistic regression revealed that the DLQI treatment domain score was the only factor associated with falls (odds ratio [OR] =8.01, 95% confidence interval [CI] =1.27-50.63, P = 0.027). Physical inactivity was associated with DLQI symptom and feeling domain scores (OR = 5.54, 95% CI = 1.26-24.33, P = 0.023) and the with-oxaliplatin or paclitaxel regimen (OR = 3.71, 95% CI = 1.06-13.03, P = 0.041). Conclusions The results of the present study suggest patients should be informed that HFS is a risk factor for physical inactivity and falls.
Collapse
Affiliation(s)
- Hiroko Komatsu
- Faculty of Nursing and Medical Care, Keio University, Tokyo, Japan
| | - Kaori Yagasaki
- Faculty of Nursing and Medical Care, Keio University, Tokyo, Japan
| | - Yasuo Hamamoto
- Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan
| | - Toru Takebayashi
- Department of Preventive Medicine and Public Health, School of Medicine, Keio University, Tokyo, Japan
| |
Collapse
|
9
|
Singh BSTP, Tripathy T, Kar BR, Singh S. Involvement of scars in capecitabine induced hand foot syndrome. Indian J Dermatol Venereol Leprol 2017; 84:85-87. [PMID: 29210360 DOI: 10.4103/ijdvl.ijdvl_11_17] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Affiliation(s)
| | - Tapaswini Tripathy
- Department of Dermatology, IMS and SUM Hospital, Bhubaneswar, Odisha, India
| | - Bikash Ranjan Kar
- Department of Dermatology, IMS and SUM Hospital, Bhubaneswar, Odisha, India
| | - Surabhi Singh
- Department of pathology, Prolife Diagnostics, Bhubaneswar, Odisha, India
| |
Collapse
|
10
|
van Erning FN, Janssen-Heijnen ML, Wegdam JA, Slooter GD, Wijsman JH, Vreugenhil A, Beijers TA, van de Poll-Franse LV, Lemmens VE. The Course of Neuropathic Symptoms in Relation to Adjuvant Chemotherapy Among Elderly Patients With Stage III Colon Cancer: A Longitudinal Study. Clin Colorectal Cancer 2017; 16:195-203. [DOI: 10.1016/j.clcc.2016.09.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2016] [Accepted: 09/08/2016] [Indexed: 12/16/2022]
|
11
|
Mukai H, Kogawa T, Matsubara N, Naito Y, Sasaki M, Hosono A. A first-in-human Phase 1 study of epirubicin-conjugated polymer micelles (K-912/NC-6300) in patients with advanced or recurrent solid tumors. Invest New Drugs 2017; 35:307-314. [DOI: 10.1007/s10637-016-0422-z] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2016] [Accepted: 12/28/2016] [Indexed: 10/20/2022]
|
12
|
Nam SH, Choi HJ, Kang WD, Kim SM, Lim MC, Park SY, Kim JS, Kim BG, Bae DS, Lee JW, Kim TJ, Song T. Development and Validation of the Korean Version of Hand-Foot Skin Reaction and Quality of Life Questionnaire (HF-QoL-K). J Korean Med Sci 2016; 31:1969-1975. [PMID: 27822937 PMCID: PMC5102862 DOI: 10.3346/jkms.2016.31.12.1969] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/23/2016] [Accepted: 08/21/2016] [Indexed: 11/22/2022] Open
Abstract
Given the growing number of cancer patients and the resulting increase in the administration of chemotherapeutic agents, convenient and effective methods for measuring the symptoms and quality of life associated with the hand-foot syndrome (HFS) are needed. Therefore, the aim of this study was to develop and validate the Korean version of the hand-foot skin reaction and quality of life questionnaire (HF-QoL-K), comprising a 20-item symptom domain and an 18-item daily activity domain. After we developed the HF-QoL-K, 209 Korean patients with gynecologic cancer who were undergoing chemotherapeutic agents relating the HFS were asked to fill in the questionnaire. The content validity, internal consistency reliability, and test-retest reliability were evaluated. The internal validity index, Cronbach's alpha coefficient, and intra-class correlation coefficient of the HF-QoL-K were 0.90, 0.958, and 0.825 (95% confidence interval [CI], 0.774-0.865), respectively. The scatter plot (Pearson correlation coefficient, 0.826) and the Bland-Altman plot for test-retest reliability were also acceptable. The HF-QoL-K instrument is a valid and reliable questionnaire for the measurement of the symptoms and quality of life in Korean cancer patients suffering HFS.
Collapse
Affiliation(s)
- Se Hyun Nam
- Department of Obstetrics and Gynecology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Hyun Jin Choi
- Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Woo Dae Kang
- Department of Obstetrics and Gynecology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea
| | - Seok Mo Kim
- Department of Obstetrics and Gynecology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea
| | - Myong Cheol Lim
- Gynecologic Cancer Branch and Center for Uterine Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea
| | - Sang Yoon Park
- Gynecologic Cancer Branch and Center for Uterine Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea
| | - Jung Sup Kim
- Korean Language and Literature, Kyung Hee University, Seoul, Korea
| | - Byoung Gie Kim
- Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Duk Soo Bae
- Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Jeong Won Lee
- Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Tae Joong Kim
- Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Taejong Song
- Department of Obstetrics and Gynecology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
| |
Collapse
|
13
|
Wang JZ, Cowley A, McLellan BN. Differentiating hand-foot syndrome from tinea in patients receiving chemotherapy. Acta Oncol 2016; 55:1061-4. [PMID: 27181134 DOI: 10.3109/0284186x.2016.1155739] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- Jenny Z. Wang
- Albert Einstein College of Medicine, Bronx, New York, USA
| | | | | |
Collapse
|
14
|
Naito M, Yamamoto T, Hara S, Shimamoto C, Miwa Y. Hemoglobin Value Is the Most Important Factor in the Development of Hand-Foot Syndrome under the Capecitabine Regimen. Chemotherapy 2016; 62:23-29. [DOI: 10.1159/000445866] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2015] [Accepted: 03/29/2016] [Indexed: 11/19/2022]
Abstract
Background: Hand-foot syndrome (HFS) is a common side effect that has a high occurrence rate with capecitabine (Cape) chemotherapy. However, little is known about the risk factors of developing HFS under the Cape regimen. Our aim was to examine these risk factors. Methods: A univariate analysis was used to determine the risk factors associated with developing HFS, and we calculated the effect sizes between the patients who developed HFS compared to those who did not. Results: Of the 52 patients enrolled in our research, 24 (46.2%) developed HFS. This group was significantly associated with hemoglobin (Hb) values (p < 0.001), and the effect size (1.21) was more than moderate. The receiver operating characteristic curve analysis confirmed 12 mg/dl Hb as the best diagnostic cut-off value for developing HFS. The sensitivity and specificity were 75.5 and 88.2%, respectively. Patients who had Hb values of 12 or below who developed HFS had longer median times without HFS compared to patients with high Hb values (115 vs. 75 days, p = 0.30, hazard ratio = 1.42, 95% CI 0.73-2.76) and a greater area under the Kaplan-Meier curves (p < 0.05). Conclusion: This research suggests that the Hb value is an important factor for developing HFS.
Collapse
|
15
|
Boers-Doets C, Lacouture M, Langenhoff J, van Zuuren EJ, Stijnen T, Brakenhoff J, Ouwerkerk J, Galimont A, Bro W, Nortier H. Interventions for skin reactions associated with targeted anticancer treatments. Hippokratia 2015. [DOI: 10.1002/14651858.cd009236.pub2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | - Mario Lacouture
- Memorial Sloan Kettering Cancer Center; Department of Medicine, Dermatology Service; 160 East 53rd St New York USA 10022
| | - Jessica Langenhoff
- Leiden University Medical Center; Walaeus Library; PO Box 9600 Leiden Netherlands 2300 RC
| | - Esther J van Zuuren
- Leiden University Medical Center; Department of Dermatology; PO Box 9600 B1-Q Leiden Netherlands 2300 RC
| | - Theo Stijnen
- Leiden University Medical Center; Department of Medical Statistics; PO Box 9600 Leiden Netherlands 2300 RC
| | - Jan Brakenhoff
- Waterland Hospital; Department of Internal Medicine; PO-box 250 Purmerend Netherlands 1440 AG
| | - Jan Ouwerkerk
- Leiden University Medical Center; Department of Clinical Oncology; PO Box 9600 Leiden Netherlands 2300 RC
| | - Annemie Galimont
- Admiraal de Ruyter Hospital; Department of Dermatology; 's-Gravenpolderse-weg 114 Goes Netherlands 4462 RA
| | - William Bro
- Kidney Cancer Association; 1234 Sherman Ave Ste 203 Evanston Illinois USA 60202
| | - Hans Nortier
- Leiden University Medical Center; Department of Clinical Oncology; PO Box 9600 Leiden Netherlands 2300 RC
| |
Collapse
|
16
|
Zhao C, Chen J, Yu B, Wu X, Dai C, Zhou C, Chen X. Effect of modified taohongsiwu decoction on patients with chemotherapy-induced hand-foot syndrome. J TRADIT CHIN MED 2014; 34:10-4. [PMID: 25102684 DOI: 10.1016/s0254-6272(14)60047-9] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVE To observe the effect of the Traditional Chinese Medicine, modified Taohongsiwu decoction, versus pyridoxine on patients with hand-foot syndrome (HFS) from capecitabine, sorafenib, and gefitinib chemotherapy for gastric, lung, breast, colon, or rectal cancer. Also, to compare quality of life of patients in each group. METHODS Patients were assigned randomly to group A or B. Group A was given modified Taohongsiwu decoction to soak hands and feet for 30 min, once daily. Group B was given 100 mg pyridoxine orally, twice daily. After a 2-week treatment, the therapeutic effect was assessed by observing three major symptoms, including pain, ulceration, and muscular atrophy. This was assessed with the HFS-14 questionnaire. RESULTS Significant differences were observed between the two groups in pain relief, and improvement of daily life, walking, and interpersonal communication (P < 0.01). No significant differences in driving ability or interpersonal relationships were found. After 2 weeks, the effective rate was 88.3% in group A, which was significantly higher than the 50% in group B (P = 0.00). CONCLUSION Modified Taohongsiwu decoction is effective in the treatment of patients with HFS. It improves patients' quality of life according to the HFS-14.
Collapse
|
17
|
Templeton AJ, Ribi K, Surber C, Sun H, Hsu Schmitz SF, Beyeler M, Dietrich D, Borner M, Winkler A, Müller A, von Rohr L, Winterhalder RC, Rochlitz C, von Moos R, Zaman K, Thürlimann BJK, Ruhstaller T. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08). Breast 2014; 23:244-9. [PMID: 24656636 DOI: 10.1016/j.breast.2014.02.005] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2013] [Revised: 11/25/2013] [Accepted: 02/14/2014] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Elevated concentrations of doxorubicin are found in eccrine sweat glands of the palms and soles. We therefore evaluated an antiperspirant as preventive treatment for palmar-plantar erythrodysesthesia (hand-foot syndrome) in patients with metastatic breast cancer treated with pegylated liposomal doxorubicin. PATIENTS AND METHODS An antiperspirant containing aluminum chlorohydrate or placebo cream was applied to the left or right hand and foot in a double-blinded manner (intra-patient randomization). The primary endpoint was the rate of grade 2 or 3 palmar-plantar erythrodysesthesia. A secondary endpoint was the patient-reported symptom burden (tingling, numbness, pain, or skin problems). Using McNemar's matched pairs design, 53 patients were needed to detect a 20% difference between the treatment and placebo sides with a significance level of 5% and power of 90%. RESULTS Grade 2 or 3 PPE occurred in 30 (58%) of 52 evaluable patients; in six patients adverse effects occurred on the placebo side but not on the treatment side, whereas one patient developed palmar-plantar erythrodysesthesia on the treatment side only (P = 0.07). Four patients developed grade 2 or 3 palmar-plantar erythrodysesthesia on their foot on the placebo side but not on the treatment side (P = 0.05). In the cohort with grade 2 or 3 palmar-plantar erythrodysesthesia there was a trend towards fewer dermatologic symptomatologies with the active treatment (P = 0.05), and no difference for other adverse events. CONCLUSION Using topical aluminum chlorohydrate as an antiperspirant appears to reduce the incidence of grade 2 or 3 palmar-plantar erythrodysesthesia following pegylated liposomal doxorubicin chemotherapy for metastatic breast cancer.
Collapse
Affiliation(s)
| | | | - Christian Surber
- Spirig Pharma Schweiz and Dermatologische Universitätsklinik, Basel, Switzerland
| | - Hong Sun
- Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
| | | | - Michael Beyeler
- Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
| | - Daniel Dietrich
- Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
| | - Markus Borner
- Medical Oncology, Spitalzentrum AG, Biel, Switzerland
| | | | | | - Lukas von Rohr
- Medical Oncology, Kantonsspital Aarau, Aarau, Switzerland
| | | | | | - Roger von Moos
- Medical Oncology, Kantonsspital Graubünden, Chur, Switzerland
| | - Khalil Zaman
- Medical Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | | | | | | |
Collapse
|
18
|
Harris CS, Wang D, Carulli A. Docetaxel-associated palmar-plantar erythrodysesthesia: A case report and review of the literature. J Oncol Pharm Pract 2013; 20:73-80. [DOI: 10.1177/1078155213475466] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Docetaxel-associated palmar-plantar erythrodysesthesia is rarely reported in literature, particularly when used in the treatment of sarcomas. Here, we report a case of docetaxel-related palmar-plantar erythrodysesthesia in a 28-year-old male with recurrent Ewing sarcoma. Although palmar-plantar erythrodysesthesia has been seen in the literature for 30 years, there has still been little progress in understanding and appropriately addressing this adverse effect. This case report and literature review illustrates an infrequently documented adverse skin reaction and discusses the etiology, presentation, and available treatment options for palmar-plantar erythrodysesthesia.
Collapse
Affiliation(s)
- Christy S Harris
- Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA
| | - Dorothy Wang
- School of Pharmacy, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA
| | - Alison Carulli
- School of Pharmacy, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA
| |
Collapse
|
19
|
Capecitabine induced Hand-Foot Syndrome: Report of two cases. Med J Armed Forces India 2012; 69:65-7. [PMID: 24532938 DOI: 10.1016/j.mjafi.2012.01.009] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2011] [Accepted: 01/17/2012] [Indexed: 11/20/2022] Open
|
20
|
Sibaud V, Dalenc F, Chevreau C, Roché H, Delord JP, Mourey L, Lacaze JL, Rahhali N, Taïeb C. HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist 2011; 16:1469-78. [PMID: 21964002 DOI: 10.1634/theoncologist.2011-0033] [Citation(s) in RCA: 68] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Hand-foot syndrome (HFS) is a common reaction to certain chemotherapies and new targeted therapies, impairing patient quality of life (QoL). However, there is currently no specific tool to measure QoL in patients with HFS. Objective. The objective was to develop and validate a HFS-specific QoL questionnaire (HFS-14). PATIENTS AND METHODS From a list of 31 items identified from a literature review and patient interview notes, item reduction and pilot testing by cognitive debriefing resulted in a final 14-item questionnaire with excellent internal reliability. Clinical validity was assessed in 43 patients with HFS by comparing the HFS-14 score according to HFS clinical grade based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 3.0, and by measuring its correlation with the Dermatology Life Quality Index (DLQI), Skindex-16, and short-form 12 health-related questionnaires and pain measurement. RESULTS The mean HFS-14 score was significantly higher in patients with clinical grade 2 and grade 3 HFS than in those with grade 1 HFS. The higher the HFS-14 score, the greater the QoL impairment. The HFS-14 score was highly correlated with the DLQI and Skindex-16 scores. In the population of patients with severe grade 3 NCI-CTCAE HFS, the HFS-14 score was significantly higher in patients having both hands and feet severely involved than in those with severe involvement of one limb (hands or feet) with the other one less severely affected. CONCLUSIONS This scale specifically developed for patients with HFS is a valid and valuable tool for measuring HFS-related QoL impairment.
Collapse
Affiliation(s)
- Vincent Sibaud
- Department of Dermatology, Institut Claudius Regaud, 31052 Toulouse Cedex, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Wolf SL, Qin R, Menon SP, Rowland KM, Thomas S, Delaune R, Christian D, Pajon ER, Satele DV, Berenberg JL, Loprinzi CL. Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol 2010; 28:5182-7. [PMID: 21060036 PMCID: PMC3020691 DOI: 10.1200/jco.2010.31.1431] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2010] [Accepted: 09/07/2010] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective preventative treatment has been definitively demonstrated. This trial was conducted on the basis of preliminary data that a urea/lactic acid-based topical keratolytic agent (ULABTKA) may prevent HFS. PATIENTS AND METHODS A randomized, double-blind phase III trial evaluated 137 patients receiving their first ever cycle of capecitabine at a dose of either 2,000 or 2,500 mg/m(2) per day for 14 days. Patients were randomly assigned to a ULABTKA versus a placebo cream, which was applied to the hands and feet twice per day for 21 days after the start of capecitabine. Patients completed an HFS diary (HFSD) daily. HFS toxicity grade (Common Terminology Criteria for Adverse Events [CTCAE] v3.0) was also collected at baseline and at the end of each cycle. The primary end point was the incidence of moderate/severe HFS symptoms in the first treatment cycle, based on the patient-reported HFSD. RESULTS The percentage of patients with moderate/severe HFS symptoms was not different between groups, being 13.6% in the ULABTKA arm and 10.2% in the placebo arm (P = .768 by Fisher's exact test). The odds ratio was 1.37 (95% CI, 0.37 to 5.76). Cycle 1 CTCAE skin toxicity was higher in the ULABTKA arm but not significantly so (33% v 27%; P = .82). No significant differences were observed in other toxicities between groups. CONCLUSION These data do not support the efficacy of a ULABTKA cream for preventing HFS symptoms in patients receiving capecitabine.
Collapse
Affiliation(s)
- Sherry L. Wolf
- From the Mayo Clinic Rochester, Rochester; Metro-Minnesota Community Clinical Oncology Program (CCOP), St. Louis Park, MN; Carle Cancer Center CCOP, Urbana; Illinois Oncology Research Association CCOP, Peoria, IL; Heartland Cancer Research CCOP, St. Louis, MO; Colorado Cancer Research Program, Denver, CO; Hawaii Minority-Based CCOP, Honolulu, HI
| | - Rui Qin
- From the Mayo Clinic Rochester, Rochester; Metro-Minnesota Community Clinical Oncology Program (CCOP), St. Louis Park, MN; Carle Cancer Center CCOP, Urbana; Illinois Oncology Research Association CCOP, Peoria, IL; Heartland Cancer Research CCOP, St. Louis, MO; Colorado Cancer Research Program, Denver, CO; Hawaii Minority-Based CCOP, Honolulu, HI
| | - Smitha P. Menon
- From the Mayo Clinic Rochester, Rochester; Metro-Minnesota Community Clinical Oncology Program (CCOP), St. Louis Park, MN; Carle Cancer Center CCOP, Urbana; Illinois Oncology Research Association CCOP, Peoria, IL; Heartland Cancer Research CCOP, St. Louis, MO; Colorado Cancer Research Program, Denver, CO; Hawaii Minority-Based CCOP, Honolulu, HI
| | - Kendrith M. Rowland
- From the Mayo Clinic Rochester, Rochester; Metro-Minnesota Community Clinical Oncology Program (CCOP), St. Louis Park, MN; Carle Cancer Center CCOP, Urbana; Illinois Oncology Research Association CCOP, Peoria, IL; Heartland Cancer Research CCOP, St. Louis, MO; Colorado Cancer Research Program, Denver, CO; Hawaii Minority-Based CCOP, Honolulu, HI
| | - Sachdev Thomas
- From the Mayo Clinic Rochester, Rochester; Metro-Minnesota Community Clinical Oncology Program (CCOP), St. Louis Park, MN; Carle Cancer Center CCOP, Urbana; Illinois Oncology Research Association CCOP, Peoria, IL; Heartland Cancer Research CCOP, St. Louis, MO; Colorado Cancer Research Program, Denver, CO; Hawaii Minority-Based CCOP, Honolulu, HI
| | - Robert Delaune
- From the Mayo Clinic Rochester, Rochester; Metro-Minnesota Community Clinical Oncology Program (CCOP), St. Louis Park, MN; Carle Cancer Center CCOP, Urbana; Illinois Oncology Research Association CCOP, Peoria, IL; Heartland Cancer Research CCOP, St. Louis, MO; Colorado Cancer Research Program, Denver, CO; Hawaii Minority-Based CCOP, Honolulu, HI
| | - Diana Christian
- From the Mayo Clinic Rochester, Rochester; Metro-Minnesota Community Clinical Oncology Program (CCOP), St. Louis Park, MN; Carle Cancer Center CCOP, Urbana; Illinois Oncology Research Association CCOP, Peoria, IL; Heartland Cancer Research CCOP, St. Louis, MO; Colorado Cancer Research Program, Denver, CO; Hawaii Minority-Based CCOP, Honolulu, HI
| | - Eduardo R. Pajon
- From the Mayo Clinic Rochester, Rochester; Metro-Minnesota Community Clinical Oncology Program (CCOP), St. Louis Park, MN; Carle Cancer Center CCOP, Urbana; Illinois Oncology Research Association CCOP, Peoria, IL; Heartland Cancer Research CCOP, St. Louis, MO; Colorado Cancer Research Program, Denver, CO; Hawaii Minority-Based CCOP, Honolulu, HI
| | - Daniel V. Satele
- From the Mayo Clinic Rochester, Rochester; Metro-Minnesota Community Clinical Oncology Program (CCOP), St. Louis Park, MN; Carle Cancer Center CCOP, Urbana; Illinois Oncology Research Association CCOP, Peoria, IL; Heartland Cancer Research CCOP, St. Louis, MO; Colorado Cancer Research Program, Denver, CO; Hawaii Minority-Based CCOP, Honolulu, HI
| | - Jeffrey L. Berenberg
- From the Mayo Clinic Rochester, Rochester; Metro-Minnesota Community Clinical Oncology Program (CCOP), St. Louis Park, MN; Carle Cancer Center CCOP, Urbana; Illinois Oncology Research Association CCOP, Peoria, IL; Heartland Cancer Research CCOP, St. Louis, MO; Colorado Cancer Research Program, Denver, CO; Hawaii Minority-Based CCOP, Honolulu, HI
| | - Charles L. Loprinzi
- From the Mayo Clinic Rochester, Rochester; Metro-Minnesota Community Clinical Oncology Program (CCOP), St. Louis Park, MN; Carle Cancer Center CCOP, Urbana; Illinois Oncology Research Association CCOP, Peoria, IL; Heartland Cancer Research CCOP, St. Louis, MO; Colorado Cancer Research Program, Denver, CO; Hawaii Minority-Based CCOP, Honolulu, HI
| |
Collapse
|